Calix Limited
Helen Fisher serves as the Managing Director and CEO of Bio Capital Impact Fund since November 2016 and holds the position of Victorian Branch Chair for AusBiotech, a key organization in Australia's biotechnology sector. In addition to these roles, Helen Fisher is a Non-Executive Director at Calix Limited, where Helen also chairs the Audit and Risk Committee, and previously served as a Non-Executive Director and Chair of the Audit and Risk Committee at Paradigm Biopharmaceuticals. Past experience includes Non-Executive Director roles at BARD1 Life Sciences Ltd and Sienna Cancer Diagnostics. Prior to focusing on the life sciences sector, Helen Fisher was a Partner at Deloitte Australia, specializing in tax until March 2018. Educational qualifications include Bachelor degrees in Laws and Science, along with Master's degrees in Laws (specializing in International Taxation) and Commerce (specializing in Accounting), all obtained from the University of Melbourne and UNSW.
This person is not in the org chart
This person is not in any teams
Calix Limited
Calix Limited (ASX: CXL) is an environmental technology company solving global challenges in industrial decarbonisation and sustainability, including CO2 mitigation, sustainable processing, batteries, biotechnology and water treatment. Calix’s patented core platform technology delivers efficient indirect heating of raw materials to enable electrification of industries, efficient capture of unavoidable emissions, and green industrial processing solutions. Its flash heating approach can also produce unique nanoporous materials with enhanced chemical and/or bio-active properties. Leveraging its core platform technology and a global network of research and development collaborations, Calix is urgently developing multiple environmental businesses that deliver positive global impact. Because there’s only one Earth. Mars is for quitters.